We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.07%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52B
AUM Growth
+$425M
Cap. Flow
+$155M
Cap. Flow %
2.81%
Top 10 Hldgs %
32.71%
Holding
141
New
18
Increased
27
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$109M
2
UTHR icon
United Therapeutics
UTHR
+$89M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$87.1M
4
BAX icon
Baxter International
BAX
+$79M
5
CI icon
Cigna
CI
+$41.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$57.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47M
3
BLU
BELLUS Health Inc.
BLU
+$36.8M
4
PGNY icon
Progyny
PGNY
+$33.3M
5
SYK icon
Stryker
SYK
+$27.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Industrials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
126
Amylyx Pharmaceuticals
AMLX
$2.17B
– –
-813,500
Closed -$23.9M
MREO
127
Mereo BioPharma
MREO
$50.2M
– –
-7,747,891
Closed -$5.48M
NKTR icon
128
Nektar Therapeutics
NKTR
$2.3B
– –
-68,937
Closed -$735K
NTLA icon
129
Intellia Therapeutics
NTLA
$1.52B
– –
-164,627
Closed -$6.14M
PGNY icon
130
Progyny
PGNY
$2.46B
– –
-1,037,912
Closed -$33.3M
PTGX icon
131
Protagonist Therapeutics
PTGX
$8.58B
– –
-301,000
Closed -$6.92M
RXST icon
132
RxSight
RXST
$252M
– –
-1,202,833
Closed -$20.1M
SRPT icon
133
CALL
Sarepta Therapeutics
SRPT
$1.65B
– –
-75,000
Closed -$10.3M
SYRE icon
134
Spyre Therapeutics
SYRE
$8.3B
– –
-71,889
Closed -$521K
XBI icon
135
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-100,000
Closed -$7.62M
XBI icon
136
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-274,000
Closed -$20.9M
MRTX
137
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-150,000
Closed -$5.58M
KDNY
138
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-2,029,300
Closed -$47M
BLU
139
DELISTED
BELLUS Health Inc.
BLU
– –
-5,108,900
Closed -$36.8M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2023 Portfolio in Review

As of Q2 2023, OrbiMed held 141 positions worth $5.52B, up 8.3% from $5.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q2 2023 filing shows 18 new, 27 increased, 28 reduced and 15 closed positions. Its largest new stake was ACELYRIN: 5,326,302 shares worth $111M. The largest sale was Bristol-Myers Squibb, an estimated $57.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q2 2023 buy was ACELYRIN: 5,326,302 shares worth $111M.
  • OrbiMed added most to Baxter International in Q2 2023, an estimated $79M increase.
  • OrbiMed's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $57.1M.
  • OrbiMed fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $47M.
  • OrbiMed's ten largest holdings make up 33% of its $5.52B portfolio in Q2 2023.
  • OrbiMed opened 18 new positions and closed 15 in Q2 2023.
  • OrbiMed's portfolio value rose 8.3% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.